Evidence map›Paper›PMID 34022131›Full record

ArticleAmerican journal of human genetics2021

Non-coding region variants upstream of MEF2C cause severe developmental disorder through three distinct loss-of-function mechanisms.

Caroline F Wright, Nicholas M Quaife, Laura Ramos-Hernández, Petr Danecek, Matteo P Ferla, Kaitlin E Samocha, Joanna Kaplanis, Eugene J Gardner, Ruth Y Eberhardt, Katherine R Chao and 24 more

Open access · greenAbstract read
In one paragraph

Article in American journal of human genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 76 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Identification of an episignature for the MEF2C-associated syndrome.European journal of human genetics : EJHG · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. The role of untranslated region variants in Mendelian disease: a review.European journal of human genetics : EJHG · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Noncoding variants are a rare cause of recessive developmental disorders in trans with coding variants.Genetics in medicine : official journal of the American College of Medical Genetics · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 18 institutions in 4 countries.

Caroline F WrightInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Royal Devon & Exeter Hospital, Exeter EX2 5DW, UK.
Nicholas M QuaifeNational Heart & Lung Institute and MRC London Institute of Medical Sciences, Imperial College London, London W12 0NN, UK; Cardiovascular Research Centre, Royal Brompton & Harefield Hospitals NHS Trust, London SW3 6NP, UK.
Laura Ramos-HernándezCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain.
Petr DanecekHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Matteo P FerlaNational Institute for Health Research Oxford Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
Kaitlin E SamochaHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Joanna KaplanisHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Eugene J GardnerHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Ruth Y EberhardtHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Katherine R ChaoAnalytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Konrad J KarczewskiAnalytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Joannella MoralesEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Cambridge CB10 1SD, UK.
Giuseppe GalloneHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Meena BalasubramanianSheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK; Academic Unit of Child Health, Department of Oncology & Metabolism, University of Sheffield, Sheffield S10 2TH, UK.
Siddharth BankaManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK; Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, UK.
Lianne GompertzManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Health Innovation Manchester, Manchester M13 9WL, UK.
Bronwyn KerrDivision of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, UK.
Amelia KirbyDepartment of Pediatrics, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA.
Sally A LynchUCD Academic Centre on Rare Diseases, School of Medicine and Medical Sciences, University College Dublin, and Clinical Genetics, Temple Street Children's University Hospital, Dublin D01 XD99, Ireland.
Jenny E V MortonWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham B4 6NH, UK.
Hailey PinzDepartment of Pediatrics, Saint Louis University School of Medicine, Saint Louis, MO 63104, USA.
Francis H SansburyAll Wales Medical Genomics Service, NHS Wales Cardiff and Vale University Health Board, Institute of Medical Genetics, University Hospital of Wales, Cardiff CF14 4AY, UK.
Helen StewartOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Britton D ZuccarelliDepartment of Neurology, University of Kansas School of Medicine-Salina Campus, Salina, KS 67401, USA.
Genomics England Research Consortium
Stuart A CookNational Heart & Lung Institute and MRC London Institute of Medical Sciences, Imperial College London, London W12 0NN, UK.
Jenny C TaylorNational Institute for Health Research Oxford Biomedical Research Centre, Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
Jane JuusolaGeneDx, Gaithersburg, MD 20877, USA.
Kyle RettererGeneDx, Gaithersburg, MD 20877, USA.
Helen V FirthHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK; East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
Matthew E HurlesHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK.
Enrique Lara-PezziCentro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain; CIBER de enfermedades CardioVasculares (CIBERCV), 28029 Madrid, Spain.
Paul J R BartonNational Heart & Lung Institute and MRC London Institute of Medical Sciences, Imperial College London, London W12 0NN, UK; Cardiovascular Research Centre, Royal Brompton & Harefield Hospitals NHS Trust, London SW3 6NP, UK.
Nicola WhiffinHuman Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1RQ, UK; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK. Electronic address: nwhiffin@well.ox.ac.uk.
Wellcome Sanger Institute · GBBroad Institute · USUniversity of Manchester · GBCentre for Human Genetics · GBRoyal Brompton & Harefield NHS Foundation Trust · GBSpanish National Centre for Cardiovascular Research · ESBirmingham Women’s and Children’s NHS Foundation Trust · GBCambridge University Hospitals NHS Foundation Trust · GBCardiff and Vale University Health Board · GBEuropean Bioinformatics Institute · GBMRC London Institute of Medical Sciences · GBOxford University Hospitals NHS Trust · GBSaint Louis University · USSheffield Children's NHS Foundation Trust · GBUniversity College Dublin · IEUniversity of Exeter · GBUniversity of Kansas · USWake Forest University · US

Funding

Medical Research Council MC_U120085815Medical Research Council MR/V037307/1Wellcome TrustWellcome Trust 220134/Z/20/ZWellcome Trust WT098051Wellcome Trust WT200990/A/16/ZWellcome Trust WT200990/Z/16/Z
6 · The paper itself

Abstract

Clinical genetic testing of protein-coding regions identifies a likely causative variant in only around half of developmental disorder (DD) cases. The contribution of regulatory variation in non-coding regions to rare disease, including DD, remains very poorly understood. We screened 9,858 probands from the Deciphering Developmental Disorders (DDD) study for de novo mutations in the 5' untranslated regions (5' UTRs) of genes within which variants have previously been shown to cause DD through a dominant haploinsufficient mechanism. We identified four single-nucleotide variants and two copy-number variants upstream of MEF2C in a total of ten individual probands. We developed multiple bespoke and orthogonal experimental approaches to demonstrate that these variants cause DD through three distinct loss-of-function mechanisms, disrupting transcription, translation, and/or protein function. These non-coding region variants represent 23% of likely diagnoses identified in MEF2C in the DDD cohort, but these would all be missed in standard clinical genetics approaches. Nonetheless, these variants are readily detectable in exome sequence data, with 30.7% of 5' UTR bases across all genes well covered in the DDD dataset. Our analyses show that non-coding variants upstream of genes within which coding variants are known to cause DD are an important cause of severe disease and demonstrate that analyzing 5' UTRs can increase diagnostic yield. We also show how non-coding variants can help inform both the disease-causing mechanism underlying protein-coding variants and dosage tolerance of the gene.

Indexed as

5' Untranslated RegionsGenetic Predisposition to DiseaseLoss of Function MutationChildCohort StudiesDevelopmental DisabilitiesDNA Copy Number VariationsExome SequencingHumansMEF2 Transcription Factors5' Untranslated RegionsMEF2C protein, humanMEF2 Transcription Factorsdevelopmental disorders, clinical genetic testing, non-coding region variants, 5' UTR variants

Identifiers

PMID34022131
PMCPMC8206381
OpenAlexW3106088748

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.